# US 2011/0257193 A1 · Fused imidazole derivatives as trpv3 antagonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0257193 A1
- Document ID: US20110257193A1
- Status: Published application
- Kind: A1
- Application number: 13/141,199
- Filed: 2009-12-23
- Published: 2011-10-20
- Earliest claimed: 2008-12-26
- Assignees: Glenmark Pharmaceuticals S.A.
- Inventors: V. S. Prasadarao Lingam; Abraham Thomas; Shantaram Kashinath Phatangare; Ajit Shankar Mindhe; Javed Yusuf Khatik; Neelima Khairatkar-Joshi; Vidya Ganapati Kattige
- Web page: https://patentgrep.com/patent/US20110257193A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 235/12: Radicals substituted by oxygen atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides transient receptor potential vanilloid (TRPV) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.

## Claims

### Claim at position 1

-25. (canceled)

### Claim 26

The compound of the formula (1):
wherein,
at each occurrence, X is independently selected from C or N, when X is N optionally oxidized to form N oxide;
at each occurrence, R1 is independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, substituted or unsubstituted alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, —S(O)pR5 (where p is 1 or 2), and —SO2NR5R6;
‘m’ is an integer ranging from 1 to 4, both inclusive;
Q is hydrogen, substituted or unsubstituted alkyl, haloalkyl, aryl, arylalkyl, heteroaryl; wherein substituents, may be one or more and are independently selected from halogen, hydroxyl, nitro, cyano, amino, COORa, C(O)NR5R6, substituted or unsubstituted alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, and cycloalkoxy;
R2 and R3, may be same or different, are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, haloalkyl, alkoxyalkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclic group, and heterocyclylalkyl;
at each occurrence, R4 is independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, amino, —COORa, substituted or unsubstituted alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl;
at each occurrence, Ra is independently hydrogen or substituted or unsubstituted alkyl;
at each occurrence, R5 and R6, may be same or different, are independently selected from hydrogen, substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, aryl and heteroaryl, cycloalkylalkyl, arylalkyl, and heteroarylalkyl; and
‘n’ is an integer ranging from 1 to 3, both inclusive;
or pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 26)

The compound according to claim 26, having the formula (II):
wherein,
at each occurrence, R1 is independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, substituted or unsubstituted alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, —S(O)pR5 (where p is 1 or 2), and —SO2NR5R6;
‘m’ is an integer ranging from 1 to 4, both inclusive;
Q is hydrogen, substituted or unsubstituted alkyl, haloalkyl, aryl, arylalkyl, heteroaryl;
wherein substituents, may be one or more and are independently selected from halogen, hydroxyl, nitro, cyano, amino, COORa, C(O)NR5R6, substituted or unsubstituted alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, and cycloalkoxy;
Ra is hydrogen or substituted or unsubstituted alkyl;
R2 and R3, may be same or different, are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, haloalkyl, alkoxyalkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclic group, and heterocyclylalkyl; and
at each occurrence, R5 and R6, may be same or different, are independently selected from hydrogen, substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, aryl and heteroaryl, cycloalkylalkyl, arylalkyl, and heteroarylalkyl;
or pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 26)

The compound according to claim 26, having the formula (III):
wherein, X is C or N, when X is N, optionally oxidized to form N oxide;
at each occurrence, Z is independently selected from C or N;
at each occurrence, R1 is independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, substituted or unsubstituted alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, —S(O)pR5 (where p is 1 or 2), and —SO2NR5R6;
‘m’ is an integer ranging from 1 to 4, both inclusive;
at each occurrence, R7 may be same or different, is independently selected from halogen, hydroxyl, nitro, cyano, amino, COORa, C(O)NR5R6, substituted or unsubstituted alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, and cycloalkoxy;
Ra is hydrogen or substituted or unsubstituted alkyl;
R2 and R3, may be same or different, are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, haloalkyl, alkoxyalkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclic group, arylalkyl, heteroarylalkyl, and heterocyclylalkyl;
at each occurrence, R5 and R6, may be same or different, are independently selected from hydrogen, substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; and
‘r’ is an integer ranging from 1 to 5, both inclusive;
or pharmaceutically acceptable salt thereof.

### Claim 29 (depends on 26)

The compound according to claim 26, wherein X is C and R1 is hydrogen.

### Claim 30 (depends on 26)

The compound according to claim 26, wherein Q is substituted or unsubstituted aryl.

### Claim 31 (depends on 30)

The compound according to claim 30, wherein aryl is substituted or unsubstituted phenyl.

### Claim 32 (depends on 26)

The compound according to claim 26, wherein Q is substituted or unsubstituted arylalkyl.

### Claim 33 (depends on 32)

The compound according to claim 32, wherein arylalkyl is benzyl.

### Claim 34 (depends on 26)

The compound according to claim 26, wherein Q is substituted or unsubstituted heteroaryl.

### Claim 35 (depends on 34)

The compound according to claim 34, wherein heteroaryl is pyridine.

### Claim 36 (depends on 26)

The compound according to claim 26, wherein R2 is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, or cycloalkylalkyl, arylalkyl.

### Claim 37 (depends on 26)

The compound according to claim 26, wherein R3 is hydrogen, substituted or unsubstituted alkyl or haloalkyl.

### Claim 38 (depends on 26)

The compound according to claim 26 wherein ‘n’ is 0.

### Claim 39 (depends on 26)

The compound according to claim 26 selected from:
2-{(E)-2-[2-(Cyclopropylmethoxy)-3-methoxyphenyl]vinyl}-1-pyridin-2-yl-1H-benzimidazole;
2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-1-pyridin-2-yl-1H-benzimidazole;
1-(5-Chloropyridin-2-yl)-2-{(E)-2-[2-(cyclopentyloxy)-3-methoxyphenyl]vinyl}-1H-benzimidazole;
2-[(E)-2-(2-[Cyclopentyloxy]-3-methoxyphenyl)vinyl]-1-(5-nitropyridin-2-yl)-1H-benzimidazole;
2-[(E)-2-(2-Benzyloxy-3-methoxyphenyl)vinyl]-1-(3,5-dichloropyridin-2-yl)-1H-benzimidazole;
or pharmaceutically acceptable salt thereof.

### Claim 40 (depends on 26)

The compound according to claim 26 selected from:
1-(3,5-Dichloropyridin-2-yl)-2-{(E)-2-[2-(2-fluorobenzyloxy)-3-methoxyphenyl]vinyl}-1H-benzimidazole;
2-{2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile;
6-{2-[(E)-2-(2-Butoxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile;
6-{2-[(E)-2-(2-Isopropoxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile;
6-{2-[(E)-2-(2-(1-Ethylpropoxy)-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile;
or pharmaceutically acceptable salt thereof.

### Claim 41 (depends on 26)

The compound according to claim 26 selected from:
6-(2-{(E)-2-[3-methoxy-2-(2-methylpropoxy)phenyl]ethenyl}-1H-benzimidazol-1-yl)pyridine-3-carbonitrile;
6-{2-[(E)-2-(2-[Cyclopropylmethoxy]-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile;
6-{2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile;
6-(2-{(E)-2-[2-(2-Fluorobenzyloxy)-3-methoxyphenyl]vinyl}-1H-benzimidazol-1-yl)nicotinonitrile;
6-{2-[(E)-2-(2-(2-Cyanobenzyloxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile;
or pharmaceutically acceptable salt thereof.

### Claim 42 (depends on 26)

The compound according to claim 26 selected from:
6-{2-[(E)-2-(3-Methoxy-2-{[2-(trifluoromethyl)benzyl]oxy}phenyl)vinyl]-1H-benzimidazole-1-yl}nicotinonitrile;
6-(2-{(E)-2-[2-(2,6-Difluorobenzyloxy)-3-methoxyphenyl]vinyl}-1H-benzimidazol-1-yl)nicotinonitrile;
6-(2-{(E)-2-[2-(2,4-Difluorobenzyloxy)-3-methoxyphenyl]vinyl}-1H-benzimidazol-1-yl)nicotinonitrile;
Ethyl 6-{2-[(E)-2-(2-[Cyclopentyloxy]-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}pyridazine-3-carboxylate;
6-{2-[(E)-2-(2-[Cyclopentyloxy]-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}pyridazine-3-carbonitrile;
or pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 26)

The compound according to claim 26 selected from:
2-{(E)-2-[2-Cyclopentyloxy)-3-methoxyphenyl]vinyl}-1-pyrimidin-2-yl-1H-benzimidazole;
1-(5-Bromopyrimidin-2-yl)-2-{(E)-2-[2-(1-ethylpropoxy)-3-methoxyphenyl]vinyl}-1H-benzimidazole;
1-(5-Bromopyrimidin-2-yl)-2-[(E)-2-(2-cyclopentyloxy-3-methoxyphenyl)vinyl]-1H-benzimidazole;
2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-1-[3-(trifluoromethyl)pyridin-2-yl]-1H-benzimidazole;
2-[(E)-2-(2-Isopropoxy-3-methoxyphenyl)vinyl]-1-(5-trifluoromethylpyridin-2-yl)-1H-benzimidazole;
or pharmaceutically acceptable salt thereof.

### Claim 44 (depends on 26)

The compound according to claim 26 selected from:
2-[(E)-2-(2-Cyclopropyloxy-3-methoxyphenyl)vinyl]-1-(5-trifluoromethylpyridin-2-yl)-1H-benzimidazole;
2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-1-[5-(trifluoromethyl)pyridin-2-yl]-1H-benzimidazole;
2-[(E)-2-(2-Benzyloxy-3-methoxyphenyl)vinyl]-1-[5-(trifluoromethyl)pyridin-2-yl]-1H-benzimidazole;
1-[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]-2-[(E)-2-(2-cyclopentyloxy-3-methoxyphenyl)vinyl]-1H-benzimidazole;
Methyl 6-(2-{(E)-2-[2-(Cyclopentyloxy)-3-methoxyphenyl]vinyl}-1H-benzimidazol-1-yl)nicotinate;
or pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 26)

The compound according to claim 26 selected from:
2-[(E)-2-(2-Cyclopropylmethoxy-3-methoxyphenyl)vinyl]-1-(4-methylphenyl)-1H-benzimidazole;
2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-1-(2-methoxyphenyl)-1H-benzimidazole;
4-{2-[(E)-2-(2-Cyclopropylmethoxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}benzonitrile;
4-{2-[(E)-2-(2-Benzyloxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}benzonitrile;
2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-1-[4-(trifluoromethyl)phenyl]-1H-benzimidazole;
or pharmaceutically acceptable salt thereof.

### Claim 46 (depends on 26)

The compound according to claim 26 selected from:
4-{2-[(E)-2-(2-Butoxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}benzonitrile;
2-[(E)-2-(2-Cyclopropylmethoxy-3-methoxyphenyl)vinyl]-1-[4-(trifluoromethyl)phenyl]-1H-benzimidazole;
5-{2-[(E)-2-(2-Cyclopropylmethoxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}-4-fluorobenzonitrile;
4-{2-[(E)-2-(2-Cyclopropylmethoxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}-3-fluorobenzonitrile;
2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-1-(4-tert-butylbenzyl)-1H-benzimidazole;
or pharmaceutically acceptable salt thereof.

### Claim 47 (depends on 26)

The compound according to claim 26 selected from:
1-(2,4-Difluorobenzyl)-2-[(E)-2-(2-cyclopropylmethoxy-3-methoxyphenyl)vinyl]-1H-benzimidazole;
4-({2-[(E)-2-(2-Cyclopropylmethoxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}methyl)benzonitrile;
4-({2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}methyl)benzonitrile;
4-({2-[(E)-2-(2-{2-Fluorobenzyloxy}-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}methyl)benzonitrile;
2-[(E)-2-(2-Cylopropymethoxy-3-methoxyphenyl)]-1-(2-thienyl)-1H-benzimidazole;
or pharmaceutically acceptable salt thereof.

### Claim 48 (depends on 26)

The compound according to claim 26 selected from:
2-[(E)-2-(2-Cyclopropyloxy-3-methoxyphenyl)vinyl]-1-(1,3-thiazol-2-yl)-1H-benzimidazole;
2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-1-(1,3-thiazol-2-yl)-1H-benzimidazole;
2-{2-[(E)-2-(2-[Cyclopentyloxy]-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}-1,3-thiazole-5-carbonitrile;
2-{2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}-4-methyl-1,3-thiazole-5-carbonitrile;
2-{2-[(E)-2-(2-Cyclopropylmethoxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}-1,3-benzothiazole;
or pharmaceutically acceptable salt thereof.

### Claim 49 (depends on 26)

The compound according to claim 26 selected from:
6-{2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-6-methoxy-1H-benzimidazol-1-yl}nicotinonitrile;
6-(6-Chloro-2-{(E)-2-[3-methoxy-2-(2-methylpropoxy)phenyl]ethenyl}-1H-benzimidazol-1-yl)pyridine-3-carbonitrile;
6-{2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-6-fluoro-1H-benzimidazol-1-yl}nicotinonitrile;
6-{6-Chloro-2-[(E)-2-(2-cyclopentyloxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile;
6-{5-chloro-2-[(E)-2-(2-cyclopentyloxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile;
or pharmaceutically acceptable salt thereof.

### Claim 50 (depends on 26)

The compound according to claim 26 selected from:
6-{2-[(E)-2-(2-[Cyclopentyloxy]-3-methoxyphenyl)vinyl]-5-methoxy-1H-benzimidazol-1-yl}nicotinonitrile;
6-{2-[(E)-2-(2-[Cyclopentyloxy]-3-methoxyphenyl)vinyl]-5-(trifluoromethyl)-1H-benzimidazol-1-yl}nicotinonitrile;
6-{6-(Difluoromethoxy)-2-[(E)-2-(2-[cyclopentyloxy]-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile;
6-{2-[(E)-2-(2-[Cyclopentyloxy]-3-methoxyphenyl)vinyl]-5-(difluoromethoxy)-1H-benzimidazol-1-yl}nicotinonitrile;
Methyl 6-{2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-6-fluoro-1H-benzimidazol-1-yl}nicotinate;
or pharmaceutically acceptable salt thereof.

### Claim 51 (depends on 26)

The compound according to claim 26 selected from:
2-{2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-5,6-difluoro-1H-benzimidazol-1-yl}nicotinonitrile;
6-{2-[(E)-2-(2-[Cyclopentyloxy]-3-methoxyphenyl)vinyl]-5,6-dimethyl-1H-benzimidazol-1-yl}nicotinonitrile;
6-{2-[(E)-2-(2-Ethoxy-3-methoxyphenyl)vinyl]-5,6-difluoro-1H-benzimidazol-1-yl}nicotinonitrile;
6-{2-[(E)-2-(2-Butoxy-3-methoxyphenyl)vinyl]-5,6-difluoro-1H-benzimidazol-1-yl}-nicotinonitrile;
or pharmaceutically acceptable salt thereof.

### Claim 52 (depends on 26)

The compound according to claim 26 selected from:
6-{5,6-Difluoro-2-[(E)-2-(2-isobutoxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile;
6-{2-[(E)-2-(2-Cyclobutylmethoxy-3-methoxyphenyl)vinyl]-5,6-difluoro-1H-benzimidazol-1-yl nicotinonitrile;
6-{5,6-Difluoro-2-[(E)-2-(2-hydroxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile;
6-{5-Chloro-2-[(E)-2-(2-cyclopentyloxy-3-methoxyphenyl)vinyl]-6-(trifluoromethyl)-1H-benzimidazol-1-yl}nicotinonitrile;
or pharmaceutically acceptable salt thereof.

### Claim 53 (depends on 26)

The compound according to claim 26 selected from:
6-{5,6-Dichloro-2-[(E)-2-(2-cyclopentyloxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile;
Ethyl 6-{2-[(E)-2-(2-cyclopentyloxy-3-methoxyphenyl)vinyl]-5,6-difluoro-1H-benzimidazol-1-yl}pyridazine-3-carboxylate;
6-{2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-5,6-difluoro-1H-benzimidazol-1-yl}pyridazine-3-carboxylic acid;
6-{2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-5,6-difluoro-1H-benzimidazol-1-yl}pyridazine-3-carboxamide;
6-{2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-5,6-difluoro-1H-benzimidazol-1-yl}pyridazine-3-carbonitrile;
or pharmaceutically acceptable salt thereof.

### Claim 54 (depends on 26)

The compound according to claim 26 selected from:
6-{2-[(E)-2-(2-(1-ethylpropoxy)-3-methoxyphenyl)vinyl]-5,6-difluoro-1H-benzimidazol-1-yl}nicotinonitrile;
6-{5,7-Difluoro-2-[(E)-2-(2-pentyloxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile;
6-{5,7-Difluoro-2-[(E)-2-(2-[cyclopentyloxy]-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile;
6-{2-[(E)-2-(2-pentyloxy-3-methoxyphenyl)vinyl]-4,5,6-trifluoro-1H-benzimidazol-1-yl}nicotinonitrile;
or pharmaceutically acceptable salt thereof.

### Claim 55 (depends on 26)

The compound according to claim 26 selected from:
6-(2-{(E)-2-[3-(Difluoromethoxy)-2-pentyloxyphenyl]vinyl}-5,6-difluoro-1H-benzimidazol-1-yl)nicotinonitrile;
6-(2-{(E)-2-[2-(Cyclobutylmethoxy)-3-difluoromethoxyphenyl]vinyl}-5,6-difluoro-1H-benzimidazol-1-yl)nicotinonitrile;
6-(2-{(E)-2-[2-(Cyclopentyloxy)-3-difluoromethoxyphenyl-]vinyl}-5,6-difluoro-1H-benzimidazol-1-yl)nicotinonitrile;
2-[(E)-2-(2-butoxy-3-methoxyphenyl)vinyl]-1-(5-trifluoromethylpyridin-2-yl)-1H-benzimidazole;
6-{2-[(E)-2-(2-Butoxy-3-methoxyphenyl)vinyl]-3H-imidazo[4,5-b]pyridin-3-yl}nicotinonitrile;
or pharmaceutically acceptable salt thereof.

### Claim 56 (depends on 26)

The compound according to claim 26 selected from:
6-{2-[(E)-2-(2-Pentyloxy-3-methoxyphenyl)vinyl]-3H-imidazo[4,5-b]pyridin-3-yl}nicotinonitrile;
6-(2-{(E)-2-[3-methoxy-2-(pentyloxy)phenyl]ethenyl}-4-oxido-3H-imidazo[4,5-b]pyridin-3-yl)pyridine-3-carbonitrile;
6-{2-[(E)-2-(2-[Cyclopropylmethoxy]-3-methoxyphenyl)vinyl]-3H-imidazo[4,5-b]pyridin-3-yl}nicotinonitrile;
6-[2-{(E)-2-[2-(Cyclobutylmethoxy)-3-methoxyphenyl]vinyl}-3H-imidazo[4,5-b]pyridin-3-yl]nicotinonitrile;
6-{2-[(E)-2-(2-[Cyclopentyloxy]-3-methoxyphenyl)vinyl]-3H-imidazo[4,5-b]pyridin-3-yl}nicotinonitrile;
or pharmaceutically acceptable salt thereof.

### Claim 57 (depends on 26)

The compound according to claim 26 selected from:
6-(2-{(E)-2-[2-(cyclopentyloxy)-3-methoxyphenyl]ethenyl}-4-oxido-3H-imidazo[4,5-b]pyridin-3-yl)pyridine-3-carbonitrile;
6-{6-Chloro-2-[(E)-2-(2-pentyloxy-3-methoxyphenyl)vinyl]-3H-imidazo[4,5-b]pyridin-3-yl}nicotinonitrile;
6-(6-Chloro-2-{(E)-2-[2-(cyclobutylmethoxy)-3-methoxyphenyl]vinyl}-3H-imidazo[4,5-b]pyridin-3-yl)nicotinonitrile;
6-{6-Chloro-2-[(E)-2-(2-(cyclopentyloxy)-3-methoxyphenyl)vinyl]-3H-imidazo[4,5-b]pyridin-3-yl}nicotinonitrile;
6-(2-{(E)-2-[3-(Difluoromethoxy)-2-pentyloxyphenyl]vinyl}-3H-imidazo[4,5-b]pyridin-3-yl)nicotinonitrile;
or pharmaceutically acceptable salt thereof.

### Claim 58 (depends on 26)

The compound according to claim 26 selected from:
6-(2-{(E)-2-[2-(Cyclobutylmethoxy)-3-difluoromethoxyphenyl]vinyl}-3H-imidazo[4,5-b]pyridin-3-yl)nicotinonitrile;
6-(2-{(E)-2-[2-(Cyclopentyloxy)-3-difluoromethoxyphenyl]vinyl}-3H-imidazo[4,5-b]pyridin-3-yl)nicotinonitrile;
2-[(E)-2-(2-Cyclobutylmethoxy-3-difluoromethoxyphenyl)vinyl]-3-[4-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridine;
2-{(E)-2-[2-Cylobutylmethoxy-3-(difluoromethoxy)phenyl]vinyl}-3-[4-(trifluoro methoxy)phenyl]-3H-imidazo[4,5-b]pyridine;
or pharmaceutically acceptable salt thereof.

### Claim 59 (depends on 26)

The compound according to claim 26 selected from:
6-(6-Chloro-2-{(E)-2-[3-(difluoromethoxy)-2-pentyloxyphenyl]vinyl}-3H-imidazo[4,5-b]pyridin-3-yl)nicotinonitrile;
6-(6-Chloro-2-{(E)-2-[2-(cyclobutylmethoxy)-3-difluoromethoxyphenyl]vinyl}-3H-imidazo[4,5-b]pyridin-3-yl)nicotinonitrile;
6-(6-Chloro-2-{(E)-2-[2-(cyclopentyloxy)-3-difluoromethoxyphenyl]vinyl}-3H-imidazo[4,5-b]pyridin-3-yl)nicotinonitrile; and
6-{2-[(E)-2-(2-[Cyclopentyloxy]-3-methoxyphenyl)vinyl]-1H-imidazo[4,5-c]pyridin-1-yl}nicotinonitrile or pharmaceutically acceptable salt thereof.

### Claim 60

A compound selected from:
6-{5,6-Difluoro-2-[(E)-2-(2-pentoxy-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile;
6-{2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-5,6-difluoro-1H-benzimidazol-1-yl}nicotinonitrile;
6-{6-Chloro-2-[(E)-2-(2-[cyclopentyloxy]-3-methoxyphenyl)vinyl]-5-fluoro-1H-benzimidazol-1-yl}nicotinonitrile; and
6-{4,6-Difluoro-2-[(E)-2-(2-[cyclopentyloxy]-3-methoxyphenyl)vinyl]-1H-benzimidazol-1-yl}nicotinonitrile or pharmaceutically acceptable salt thereof.

### Claim 61 (depends on 26)

A pharmaceutical composition comprising a compound according claim 26, either as a free base or pharmaceutically acceptable salt form and a pharmaceutically acceptable excipient.

### Claim 62 (depends on 61)

The pharmaceutical composition according to claim 61, wherein the pharmaceutically acceptable excipient is a carrier or diluent.

### Claim 63 (depends on 26)

A method for preventing, ameliorating or treating a disease, disorder, syndrome or condition modulated by a vanilloid receptor in a subject in need thereof said method comprising administering to said subject a therapeutically effective amount of a compound according to claim 26.

### Claim 64 (depends on 63)

The method according to claim 63, wherein the vanilloid receptor is TRPV3

### Claim 65 (depends on 63)

The method according to claim 63 wherein the disease, disorder, syndrome or condition is selected from the group consisting of pain, acute pain, chronic pain, nociceptive pain, neuropathic pain, post-operative pain, dental pain, cancer pain, cardiac pain arising from an ischemic myocardium, pain due to migraine, arthralgia, neuropathies, neuralgia, trigeminal neuralgia nerve injury, diabetic neuropathy, neurodegeneration, retinopathy, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, urinary incontinence, vulvodynia, gastrointestinal disorders such as irritable bowel syndrome, gastro-esophageal reflux disease, enteritis, ileitis, stomach-duodenal ulcer, inflammatory bowel disease, Crohn's disease, celiac disease, an inflammatory disease such as pancreatitis, a respiratory disorder such as allergic and non-allergic rhinitis, asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, dermatitis, pruritic conditions such as uremic pruritus, fervescence, muscle spasms, emesis, dyskinesias, depression, Huntington's disease, memory deficits, restricted brain function, amyotrophic lateral sclerosis (ALS), dementia, arthritis, rheumatoid arthritis, osteoarthritis, diabetes, obesity, urticaria, actinic keratosis, keratocanthoma, alopecia, Meniere's disease, tinnitus, hyperacusis, anxiety disorders and benign prostate hyperplasia.

### Claim 66 (depends on 65)

The method according to claim 65 wherein the disease, disorder, syndrome or condition is pain.

### Claim 67 (depends on 66)

The method according to claim 66, wherein the pain is acute pain.

### Claim 68 (depends on 66)

The method according to claim 66, wherein the pain is chronic pain.

### Claim 69 (depends on 66)

The method according to claim 66, wherein the pain is post-operative pain.

### Claim 70 (depends on 65)

The method according to claim 65 wherein the disease, disorder, syndrome or condition is osteoarthritis.

### Claim 71 (depends on 65)

The method according to claim 65 wherein the disease, disorder, syndrome or condition is rheumatoid arthritis.

### Claim 72 (depends on 66)

The method according to claim 66 wherein the pain is neuropathic pain.

### Claim 73 (depends on 65)

The method according to claim 65 wherein the disease, disorder, syndrome or condition is inflammation.

### Claim 74 (depends on 26)

The compounds of claim 26, or pharmaceutically acceptable salts thereof, that possess IC50 value of less than 100 nM as measured by a 45Calcium uptake assay.
